Recombinant human erythropoietin (rHuEPO) in combination with chemotherapy increases breast cancer metastasis in pre-clinical mouse models

Benjamin D. Hedley 1*, Jenny E. Chu2,3*, D. George Ormond 2, Michel S. Beausoleil2,3, Alexandra Boasie 2, Alison L. Allan2,3,4, and Anargyros Xenocostas1,2,3,4,5§

Division of Hematology1 and London Regional Cancer Program2, London Health Sciences Centre; Departments of Anatomy and Cell Biology3, Oncology4, and Medicine5, Schulich School of Medicine and Dentistry, University of Western Ontario; London, Ontario, CANADA.

* These two authors contributed equally to the preparation of this manuscript.

§ Correspondence/reprint requests should be addressed to:
Anargyros Xenocostas, MD
Division of Hematology
London Health Sciences Centre-VH
800 Commissioners Rd., East, Rm A2-401
P.O. Box 5010, Stn B
London, ON Canada N6A 5W9
Tel: (519) 685-8631
Fax: (519) 685-8477
E-mail: Anargyros.Xenocostas@lhsc.on.ca

This work was supported by funding from Janssen-Ortho Canada and the London Regional Cancer Program (ALA and AX); and by a grant from the Canada Foundation for Innovation (#13199) (ALA). JEC is supported by graduate scholarships from the National Sciences and Engineering Council, the Canadian Institutes for Health Research (CIHR) Strategic Training Program and the Translational Breast Cancer Research Unit, London Regional Cancer Program. ALA is supported by a CIHR New Investigator Award and an Early Researcher Award from the Ontario Ministry of Research and Innovation.

Running Title: rHuEPO increases breast cancer metastasis

Key words: Metastasis, Breast cancer, Erythropoietin, Chemotherapy Preclinical models
STATEMENT OF TRANSLATIONAL RELEVANCE

Erythropoiesis-stimulating agents (ESAs) are used clinically for treating cancer-related anemia (CIA). Recent clinical trials have reported increased adverse events/reduced survival in ESA-treated cancer patients receiving chemotherapy, potentially related to erythropoietin (EPO)-induced cancer progression. However, minimal pre-clinical data is available regarding the underlying causes of these observations.

This manuscript describes the effects of recombinant human erythropoietin (rHuEPO) on metastatic potential and chemotherapy response of human breast cancer cells using \textit{in vitro} assays and pre-clinical animal models of metastasis. To the best of our knowledge, this is the first study to demonstrate potentiating effects on metastasis and reduction of chemotherapeutic efficacy in secondary sites by rHuEPO.

Despite concerns for disease progression related to ESA use for treatment of CIA, there are few if any studies addressing the question of metastasis. Thus, the novel findings presented here demonstrate for the first time positive effects on metastasis by rHuEPO in a clinically-relevant animal model.
ABSTRACT

**Purpose:** Erythropoiesis-stimulating agents (ESAs) are used clinically for treating cancer-related anemia. Recent clinical trials have reported increased adverse events and reduced survival in ESA-treated breast cancer patients receiving chemotherapy, potentially related to erythropoietin (EPO)-induced cancer progression. However, minimal pre-clinical data is available regarding the impact of EPO on metastatic cell behavior and/or the metastatic process, and this was the goal of our study.

**Experimental Design:** Breast cancer cell lines were treated with recombinant human EPO (rHuEPO) and screened for expression of EPOR. MDA-MB-231 and MDA-MB-435 cell lines were used for functional assays *in vitro* (2D/3D growth, survival) and *in vivo* (tumorigenicity, metastasis), in the presence or absence of EPO and/or cytotoxic agents.

**Results:** A large variation in EPOR expression across cell lines was observed. *In vitro*, rHuEPO had a protective effect on radiation-treated MDA-MB-435 cells (p<0.05), however rHuEPO treatment alone or combined with chemotherapy or hypoxia did not influence cell survival. *In vivo*, rHuEPO increased lung metastases in immunocompromised mice injected with MDA-MB-231 or MDA-MB-435 cells and treated with chemotherapy relative to mice treated with chemotherapy alone (p<0.05).

**Conclusions:** The lack of an *in vitro* effect of rhEPO highlights the importance of *in vivo* studies to delineate the effects of EPO on the metastatic process. These studies may begin to uncover the underlying functional explanation for the observed EPO-related adverse events and decreased survival in ESA-treated metastatic breast cancer patients undergoing chemotherapy.
INTRODUCTION

Over the past few decades, understanding of the physiologic function of erythropoietin (EPO) has evolved significantly. After being produced in the fetal liver or adult kidney, EPO binds to erythropoietin receptors (EPOR), initiating signaling that stimulates growth, inhibits apoptosis and induces the differentiation of erythroid progenitors to increase red blood cell mass (1). Originally known to be a critical component in the regulation of erythropoiesis, EPO has additionally been shown to exert tissue-protective effects on multiple tissues (2), suggesting a pleiotropic mechanism of action.

Following initial cloning and publishing of the human EPO gene sequence in 1985 (3), efforts were made to make recombinant human EPO (rHuEPO) and other erythropoiesis stimulating agents (ESAs) an accessible treatment for anemia. Chronic anemia and/or chemotherapy-induced anemia (CIA) is a frequent side effect in cancer patients, is associated with reduced quality-of-life, and may also enhance emergence of hypoxia-induced treatment resistance (4). In early studies, rHuEPO was shown to be a safe and effective treatment for CIA, reducing numbers of required transfusions and increasing patient quality-of-life (5). Recent meta-analyses have demonstrated that ESA treatment results in an increased risk for venous thromboembolism (VTE) in cancer patients. In addition, these meta-analyses have provided conflicting data indicating that ESAs may or may not negatively impact overall patient survival, raising concerns about the potential for disease progression leading to increased mortality rates in cancer patients (6-9).
There have been multiple trials evaluating the effect of ESAs on patients with breast cancer (5, 10-15). Of these, two studies (BRAVE and BEST) included only patients with metastatic disease (10, 11). The BRAVE study evaluated a once-weekly dose of rHuEPO and detected no difference in overall survival (10). The BEST study was ended early due to a higher mortality rate at 12 months in the rHuEPO-treated versus placebo arm (11). Additional trials in other cancer types such as the ENHANCE (head and neck cancer), EPO-CAN 20 (non-small cell lung cancer), and GOG 191 (cervical cancer) trials reinforced these concerns by reporting shorter progression-free survival and/or overall survival in patients treated with rHuEPO (16). Taken together, these clinical studies raise the question of whether there is an underlying EPO-tumor cell interaction that may lead to disease progression.

EPOR has been shown to be expressed in normal and malignant cells (17). Many of these studies have relied on anti-EPOR antibodies that have since been demonstrated to be non-specific (18), detecting either proteins of incorrect molecular weight or detecting non-EPOR proteins of a similar weight to EPOR (19). In addition, there is no universally accepted molecular weight of EPOR due to cell type specific post-translational modifications or alternative splicing which may alter the apparent size(s) of EPOR on western blots (19-21). *In vitro* studies using tumor cell lines have reported conflicting results, with some studies reporting a functional effect of rHuEPO on the proliferative behavior of cell lines (22, 23), while others demonstrate a null effect (24, 25). Variable methodological approaches were used in these conflicting studies with some limited to histopathological, biochemical, or *in vitro* evaluation, thus highlighting the need for a more complete functional assessment of the influence of rHuEPO on tumor
progression (17). Clinical disease progression in solid tumors requires evolution from localized disease to metastatic disease, often leading to patient death. Previous studies have investigated the effect of rHuEPO on cell lines in vitro or on the primary tumor, but have not yet examined effects on metastasis in vivo.

The goal of the current study was therefore to test the hypothesis that rHuEPO can influence metastatic cell behavior and/or the metastatic process in pre-clinical models of breast cancer. We first examined tumor cell lines for EPOR and EPO expression using multiple approaches. We next assessed the effects of rHuEPO on malignant potential in vitro. Finally, we used clinically relevant in vivo models of breast cancer tumorigenicity and spontaneous metastasis to determine the role of rHuEPO in disease progression. Our novel findings demonstrate that that rHuEPO can reduce the efficacy of chemotherapy in the metastatic setting in vivo, and in some cases enhance the inherent metastatic growth potential of human breast cancer cells.

MATERIALS AND METHODS

Cell lines and reagents

Cell lines and culture conditions used are listed in Supplemental Table 1. All media were purchased from Invitrogen (Carlsbad, CA). Fetal bovine serum (FBS) was purchased from Sigma (St. Louis, MO). Murine bone marrow (mBM) was obtained by aspiration from the tibia/femurs of nude mice into Hank’s Balanced Salt Solution (HBSS) (Sigma).
PCR analysis

Cells were exposed to serum-free media ± rHuEPO (10U/mL; EPREX®, Janssen-Ortho Canada, Toronto, ON) for 5 min prior to harvesting. RNA was isolated using TRIzol (Invitrogen) as per the manufacturer’s instructions. Isolated RNA was converted to cDNA by SuperScript III Reverse Transcriptase [0.5μg oligo dT12-18, 0.5mM dNTP, 1X Strand Buffer, 50mM DTT, 40U RNase Out, 200U Superscript III Reverse Transcriptase per μg RNA] (Invitrogen), with incubations at 50°C for 45 minutes followed by 70°C for 15 minutes. RT-PCR primers and cycling conditions are described in Supplemental Table 2.

Western blot analysis

Cells were exposed to serum-free media ± rHuEPO (10U/mL) for 5 min prior to harvesting. Total protein samples consisting of 30μg (cell lines), 15μg (mBM), or 0.5 μg (rHuEPOR) (R&D Systems, MN) were used for sodium dodecyl sulfate polyacrylamide gel electrophoresis (10%). Following electrophoresis, proteins were transferred onto polyvinylidene difluoride membranes (ImmobilonTM, Millipore; Bedford, MA). Blocking and antibody dilution was done using 5% skim milk in Tris-buffered saline with 0.1% Tween-20. Due to previous observations noting the non-specificity of commercially available EPOR antibodies (18), a panel of previously published and non-published primary antibodies was evaluated for EPOR binding (Supplemental Table 3). To confirm antibody specificity, primary antibodies were also pre-incubated with a two-fold excess of rHuEPOR overnight prior to use in immunoblotting. The most consistent and specific primary antibody was determined to be mouse anti-human EPOR MAB307 (R&D
Systems; 1:2000). Loading consistency was verified using mouse anti-actin antibody (Sigma; 1:2000). The secondary antibody was goat anti-mouse conjugated to horseradish peroxidase (Calbiochem, San Diego, CA; 1:2000). Proteins were visualized using Amersham™ ECL plus Chemiluminescent system (GE Healthcare, Mississauga, ON).

Flow cytometry analysis

Cells were harvested into single-cell suspensions in ice-cold flow buffer (phosphate-buffered saline [PBS]+2% FBS). The anti-EPOR antibody used was MAB307 (R&D Systems). The secondary antibody used was a phycoerythrin (PE) conjugated anti-mouse antibody (BD Biosciences, Franklin Lakes, NJ). Non-specific binding was accounted for using an IgG1 isotype control antibody (Cedarlane Laboratories, Hornby, ON). Samples were incubated sequentially with primary and secondary antibodies (1 μg/10⁶ cells) and re-suspended in cold flow buffer prior to analysis on an EPICS XL-MCL flow cytometer (Beckman Coulter, Mississauga, ON).

Enzyme linked immunosorbent assay (ELISA)

Secretion of rHuEPO by cancer cell lines was assessed by an EPO-specific ELISA (Stem Cell Technologies, Vancouver, BC). Conditioned media was prepared as described previously (26). Volumes were normalized to an equivalent of 1x10⁵ cells and absorbance at 450nm was recorded by a BioRad plate reader. Values were compared to a standard curve generated by rHuEPO in order to quantify the amount of rHuEPO secreted by cancer cell lines.
Anchorage-dependent growth assays

MDA-MB-231 or MDA-MB-435 cells (harvested at 70-80% confluency) were plated on 60mm dishes (5.0x10^4 cells/dish; n=3/time point) ± rHuEPO (10U/mL) in normal growth media containing serum. Triplicate plates were harvested and counted by hemocytometer every 48 hours for 14 days. Doubling time was calculated according to 

\[ T_d = \frac{t \cdot \ln 2}{\ln \left( \frac{N_t}{N_0} \right)} \]

(t= time of the experiment [hrs], \( N_t \)=number of cells after time \( t \), \( N_0 \)=initial number of cells plated).

Plating efficiency/colony formation assay

MDA-MB-231 and MDA-MB-435 cells were seeded onto 100mm dishes (n=3;100 cells/dish) ± rHuEPO (10U/mL) and incubated for 2 weeks to determine the effect on plating efficiency/colony formation. Plates were fixed with 1% gluteraldehyde in PBS, stained with hematoxylin, and quantified for number and size of colonies using ImageJ software (NIH, Bethesda, MD).

Anchorage-independent growth assay

Anchorage-independent growth assays were performed as previously described(26) in normal growth media ± rHuEPO (10U/mL) for 3-4 weeks. Plates were fixed in 10% neutral buffered formalin and scanned at 100X magnification. Colonies ≥20 μm were counted and scored using ImageJ software.
In vitro cytotoxic treatment

MDA-MB-231 and MDA-MB-435 cells were plated in triplicate in 6-well dishes (1x10^5 cells/well) for chemotherapy and radiation experiments, or 60mm dishes (5x10^5 cells/dish) for hypoxia ± rHuEPO (10U/mL). Cells were treated with chemotherapy (10 mg/mL Paclitaxel; 24 hours), radiation (two 5 Gy fractions, 24 hours apart, from a Cobalt 60 irradiator) or hypoxia (24 [MDA-MB-231] or 48 [MDA-MB-435] hours of treatment in 1% O₂, 5% CO₂, 94% N₂ with normoxic controls incubated in 5% CO₂). The media and any floating/dead cells in the media were then collected, combined with cells harvested by trypsinization, and subjected to centrifugation. Cells were stained with propidium iodide (50μg/mL) for 30 minutes and analyzed for viability on an EPICS XL-MCL flow cytometer.

In vivo tumorigenicity and metastasis assays

Animal procedures were performed in accordance with protocols approved by the University of Western Ontario Council on Animal Care. MDA-MB-435 and MDA-MB-231 cells were suspended in HBSS (Sigma) at a concentration of 2x10^7 cells/mL. 100μL was injected into the second thoracic mammary fat pad of 6-7 week-old female mice as described elsewhere(26). Athymic nude mice (Hsd:Athymic Nude-Foxn1nu [nu/nu]; Harlan Sprague-Dawley, Indianapolis, IN) were injected with MDA-MB-435 cells, and non-obese diabetic severe combined immunodeficient mice (NOD.CB17-Prkd-SCID/NCrHsd [NOD/SCID]; Harlan Sprague-Dawley) were injected with MDA-MB-231 cells. Tumor volume (mm³) was determined using weekly caliper measurements in 2 perpendicular dimensions and calculated using the formula:
Volume=0.52 • (width)^2 • (length). Mice were sacrificed 12 weeks post-injection and tissues were collected for analysis.

In order to determine an *in vivo* dose of rHuEPO that would minimize adverse effects of polycythemia and VTE, mice were injected with either MDA-MB-231 or MDA-MB-435 cells as described above. Three weeks post-injection, control cohorts received weekly saline subcutaneous injections (n=4), while other groups received rHuEPO (300 U/kg, 600 U/kg, or 1200 U/kg [n=4 per group]). Blood was collected via weekly saphenous vein puncture and hemoglobin (Hb) levels were determined by colorimetric assay (BioPacific Diagnostics; Vancouver, BC) at each time point. Assay results were validated at endpoint using a calibrated clinical LH780 hematology analyzer (Beckman Coulter) by determining Hb levels in blood obtained through cardiac puncture. Correlation between methods is shown in Supplemental Table 4.

To investigate any potential chemoprotective effects of rHuEPO, mice were injected with either MDA-MB-231 or MDA-MB-435 cells as noted above. Of four cohorts (n=12/group), the first group received weekly subcutaneous injections of saline, the second received 300U/kg/weekly rHuEPO, the third received 10mg/kg/weekly Paclitaxel, and the fourth received 300U/kg/weekly rHuEPO in combination with 10mg/kg/weekly Paclitaxel. Treatments were initiated 3 weeks post tumor-injection (rHuEPO), and 5 weeks post-injection (Paclitaxel) when tumors reached their exponential growth phase.

At endpoint, lungs were collected and fixed in 10% neutral-buffered formalin and embedded in paraffin such that all 5 lung lobes could be sectioned in one plane. 4μm thick sections (n=2 per mouse) were subjected to standard haematoxylin and eosin staining. The entire cross-sectional area of the tissues was captured by light microscopy.
and metastatic tumor burden and lesion size was quantified in a blinded manner using ImageJ software as previously described (26).

**Statistical analysis**

*In vitro* assays were performed at least in triplicate. *In vivo* studies were carried out using multiple animals (n=4-12/group). All data was compiled for analysis. Statistical analysis was performed using GraphPad Prism 4.0 software© (San Diego, CA) using t-tests (between two groups) or ANOVA (between three or more groups) with Tukey post-tests for normally distributed data, and Dunn’s post-tests for non-normal data. In all cases, differences were considered statistically significant when p≤0.05.

**RESULTS**

**EPOR mRNA and protein expression levels**

We first investigated the expression of EPOR and related molecules in a panel of normal and malignant cell lines using RT-PCR, immunoblotting, and flow cytometry. At the mRNA level, EPOR amplicons of 288bp (murine) and 290bp (human) were observed in all samples, with the highest intensities seen in the expected positive controls (mBM, UT7/EPO leukemia cells, and EPO-treated H838 lung cancer cells) (27). We also investigated expression of JAK2 as an important downstream tyrosine kinase in the EPO signaling cascade (28). With the exception of the H838 cell line, JAK2 mRNA was present in all cell lines tested at the expected sizes of 342bp (murine) and 396bp (human) (*Figure 1A, Supplemental Figure 1*).
Western blot analysis using MAB307 (R&D systems) revealed multiple bands, notably a band at ~75 kDa in the positive control (UT7/EPO) and another at ~55-60 kDa in both the UT7/EPO and mBM controls (Figure 1B). The 75kDa band was also observed in 3T3 and 4T1 murine cell lines. The 55-60 kDa band was additionally seen in untreated H838 and MDA-MB-231 samples, but was absent in rHuEPO-treated samples of the same cell lines. Interestingly, when the anti-EPOR antibody was pre-incubated with a two-fold excess of rHuEPOR, the 55-60 kDa band was no longer detected (Figure 1C), indicating that MAB307 was specifically binding to EPOR at this size.

Flow cytometry analysis using the MAB307 antibody demonstrated that UT7/EPO and H838 cells expressed cell surface EPOR, while MDA-MB-435, MDA-MB-231, MDA-MB-468 and 4T1 cell lines all produced negative results relative to the IgG isotype control (Figure 1D). Pre-treatment of cells with rHuEPO did not result in any change in EPOR cell surface expression relative to untreated cells (data not shown).

To determine any potential autocrine effect, an ELISA assay was used to investigate the level of endogenous EPO secreted by breast cancer cell lines. None of the cell lines tested produced enough endogenous EPO to surpass the sensitivity threshold of the assay (1.6 U/L of EPO; hashed line) (Figure 1E).

**rHuEPO does not influence in vitro growth of human breast cancer cell lines**

We next evaluated the influence of rHuEPO on breast cancer cell function using *in vitro* assays that are representative of cell behaviors important to the metastatic process. Two human breast cancer cell lines were used; moderately metastatic MDA-MB-231 cells and highly metastatic MDA-MB-435 cells. These cell lines were chosen
for further functional assays because of their differing metastatic abilities and their expression of EPOR at the mRNA and/or protein level.

In normal (2 dimensional) culture, we observed that doubling times were not significantly influenced by rHuEPO treatment for either cell line (Figure 2A), nor was plating efficiency/colony formation (Figure 2B). Assessment of anchorage-independent (3-dimensional) growth in soft agar also demonstrated no significant difference in either the number (Figure 2C) or diameter (Figure 2D) of colonies formed (p>0.05).

**rHuEPO exerts a partial protective effect on human breast cancer cells in response to specific in vitro cytotoxic treatments**

Given the conflicting literature on whether or not EPO can exert cell-protective effects on tumor cells (29), we investigated this question in vitro using clinically relevant treatment modalities in combination with rHuEPO. Following radiation therapy, a significant difference was seen in cell survival for both MDA-MB-231 and MDA-MB-435 cell lines (p<0.005) (Figure 3A). Although irradiated MDA-MB-231 cells exhibited no significant difference in survival in the presence of rHuEPO (p=0.06), irradiated MDA-MB-435 cells did demonstrate a small but significant increase in survival upon rHuEPO treatment (p=0.05). Treatment with the commonly used chemotherapeutic Paclitaxel(30) induced a significant decrease in survival relative to control for both MDA-MB-231 and MDA-MB-435 cells (p<0.01) (Figure 3B). Treatment of both cell lines with rHuEPO in conjunction with Paclitaxel had no significant protective effect on survival (p>0.05). Under hypoxic conditions, we observed that both MDA-MB-231 and MDA-MB-435 cell survival significant decreased relative to untreated controls (p<0.01), and that rHuEPO exerted no hypoxia-protective effect (p>0.05) (Figure 3C).
rHuEPO reduces the efficacy of chemotherapy on metastasis and enhances the inherent metastatic growth potential of human breast cancer cells

Mimicking specific steps in metastasis in vitro allows for controlled experiments, however only in vivo experiments allow us to evaluate the effects of rHuEPO on the entire process of breast cancer disease progression. Thus, we next examined the effect of rHuEPO on the tumorigenic and metastatic behavior of breast cancer cells in vivo.

Initial pilot dose-finding experiments were carried out in which MDA-MB-231 or MDA-MB-435 cells were injected into the mammary fat pad of NOD/SCID or nude mice, respectively (n=4/group). Three weeks post-injection, treatment with rHuEPO was initiated using a dose range of rHuEPO (300, 600, or 1200U/kg) (Supplemental Figure 2). Doses were chosen to reflect the dose ranges used for clinical treatment of CIA (300-600U/kg)(31) and for tissue protection in experimental models (1200U/kg)(2). rHuEPO had no significant influence on primary tumor growth regardless of dose level (Supplemental Figure 2A,E). However, assessment of spontaneous metastasis to the lung (Supplemental Figure 2B-D,F-H) suggested a potential metastasis-promoting effect of rHuEPO, particularly with regards to the metastatic lesion size (p=0.043) and lesion number (p=0.002) in mice injected with MDA-MB-231 cells and treated with 300U/kg rHuEPO (Supplemental Figure 2C,D). Hemoglobin was monitored weekly to determine if dosing at these levels would elevate Hb and/or cause VTE. All groups showed a dose-dependent increase in mean Hb after 9 weeks of treatment (Supplemental Table 4), and no unexplained morbidity or mortality was observed. Based on these results and the fact that a dose of 300U/kg is within the clinical dose range used to treat CIA in cancer.
patients (31), 300U/kg was chosen for the subsequent combination treatment experiments.

In NOD/SCID mice injected with MDA-MB-231 human breast cancer cells, we observed that rHuEPO treatment alone significantly increased the mean primary tumor volume at endpoint relative to untreated mice (p<0.001) (Figure 4A). However, when MDA-MB-435 human breast cancer cells were injected into nude mice, no significant difference was observed in primary tumor volume between the 4 treatment groups (Figure 4B). In both cell line models, the tumor growth rate over time was not significantly different between groups. In addition, rHuEPO did not exert any chemoprotective effect on the primary tumor volume in vivo at any time point (p>0.05).

Having established the effects of rHuEPO in the presence or absence of chemotherapy on the primary tumor, we next investigated the influence of rHuEPO on spontaneous metastasis to the lung. We first assessed the incidence of lung metastases (# mice/group showing histological metastases). With the exception of mice injected with MDA-MB-231 cells and treated with Paclitaxel (who developed no metastases) (p<0.005), there was no significant difference in metastatic incidence between treatment groups (Figure 5A,D). However, strikingly, in both cell line models we observed that rHuEPO treatment combined with Paclitaxel resulted in a significant increase in lung metastasis size relative to Paclitaxel treatment alone (p<0.001) (Figure 5C,F), suggesting a chemoprotective effect at the metastatic site. With regards to lung tumor burden (% lung area occupied by tumor), it was observed that mice injected with MDA-MB-231 cells and treated with rHuEPO in combination with Paclitaxel had a significant increase
in lung tumor burden relative to mice treated with Paclitaxel alone (p<0.001), with a similar trend observed in mice injected with MDA-MB-435 cells (Figure 5B,E).

**DISCUSSION**

Although EPO and EPOR have a well-established functional role in erythropoiesis and tissue protection, their influence on tumor progression remains controversial(2). EPOR has been found to be expressed in several normal and malignant cell lines, various normal tissues, and by many types of cancer (17). However, conflicting reports have shown the non-specificity of many anti-EPOR antibodies, raising questions about the validity of some of these expression studies (18). In addition, *in vitro* and *in vivo* studies using tumor cell lines have yielded conflicting reports with regards to the influence of ESAs on tumor cell behavior and the potential association with risk versus benefit of using ESAs to treat clinical cancer-related anemia (22-25).

From a clinical perspective, multiple trials have been carried out to evaluate the effect of ESAs on patients with breast cancer (5, 10-13, 15, 32, 33), although only two of these published studies (BRAVE and BEST) have been limited to patients with metastatic disease (10, 11). However, these studies contradict each other in their findings, with the BRAVE study detecting no difference in overall survival between treatment arms (10), while the BEST study was ended early due to a higher mortality rate in the rHuEPO-treated versus placebo arm (11). Taken together, these studies raise the question of whether there is an underlying EPO-tumor cell interaction that may lead to disease progression. However, previous pre-clinical studies have limited their investigations to
the effect of rHuEPO on the primary tumor or on cell lines in vitro, and have not investigated the role of rHuEPO in the setting of metastatic disease.

In light of unanswered questions regarding the safety of ESAs and the limitations of previous published experimental studies, there remained a need for a well-controlled and comprehensive assessment of the functional influence that rHuEPO has on cancer disease progression using clinically-relevant model systems (17). The goal of the current study was therefore to test the hypothesis that rHuEPO can influence metastatic cell behavior and/or the metastatic process in pre-clinical models of breast cancer. We first examined tumor cell lines for EPOR using multiple approaches, then assessed the effects of rHuEPO on malignant cell behaviors in vitro, and finally used clinically relevant in vivo models of breast cancer disease progression to determine the role of rHuEPO in metastasis.

Our in vitro results indicate that determining protein expression of EPOR by western blot and flow cytometry varies considerably depending on the antibody used. All three commonly used metastatic breast cancer cells lines that we assessed (MDA-MB-231, MDA-MB-435, and MDA-MB-468) expressed EPOR mRNA, although at much lower levels than known EPOR-positive cell lines. In addition, all breast cancer cell lines expressed JAK2, an important downstream signaling component of the EPO/EPOR pathway (34). However, analysis of EPOR expression by immunoblotting and flow cytometry in the same panel of breast cancer cell lines showed discordance between mRNA and protein expression, with only MDA-MB-231 cells expressing EPOR protein (as assessed by immunoblotting), and no cell line showing positive cell surface expression of EPOR (as assessed by flow cytometry). Our results are in agreement with a
recent study by Swift et al. that showed little expression of EPOR in sixty-six commonly used cell lines from various tumor types (35). Our evaluation of four anti-human EPOR antibodies found varying results between antibodies, leading us to have concerns about the specificity of these antibodies, concerns also raised by other studies (18, 25, 36). Our results also highlight the need for positive and negative controls when assessing EPOR expression. UT7/EPO and H838 cell lines were used as positive controls for PCR, immunoblotting, and flow cytometry experiments (27). These cell lines revealed a positive mRNA signal, an appropriately sized band in western blots (which disappeared with pretreatment with rHuEPOR), and positive cell surface expression by flow cytometry. With a known EPOR positive cell line, H838, we observed discordant results with mRNA expression absence in untreated cells but protein present by western blot and the converse seen when H838 cells were treated with rHuEPO. The only breast cancer cell line to show EPOR protein expression was also positive for EPOR mRNA, however both signals disappeared upon treatment with rHuEPO (due to rapid internalization of the receptor). Having used multiple controls (blocking with rHuEPOR, UT7 cells, murine bone marrow, H838, and 3T3 cells) to determine specificity to EPOR these discordant results suggest that MAB307 may have limited specificity to EPOR. The limitations may be due to the EPOR protein being differently post-translationally modified thus obscuring the protein to the mAb resulting in the discordant results seen in Figures 1A,B,C,D. Taken together, we believe that the MAB307 anti-EPOR antibody that we used in our final expression studies may show variable results and lack specifically in detecting all variants of human EPOR. To accurately determine EPOR protein expression new
antibodies must be generated that have been rigorously tested and accurately and sensitively detect EPOR such as in the work described by Elliott et al. (21).

In order to determine if even very low expression of EPOR could influence tumor cell ability to complete individual steps in the metastatic process, we performed in vitro assays mimicking various steps in metastasis in the presence or absence of rHuEPO, including the initiation and maintenance of growth and survival under stress. Two-dimensional and three-dimensional growth in the presence or absence of rHuEPO was unaffected, indicating that rHuEPO does not directly increase the growth of either MDA-MB-231 or MDA-MB-435 cells. However, direct effects have been seen with breast cancer cells that express functional surface EPOR as seen in work by Shi et al (37). Since recent clinical studies have shown decreased survival of patients treated with rHuEPO when treated concurrently with chemotherapy or radiotherapy (11, 38), we decided to investigate whether in vitro dosing of rHuEPO could increase tumor cell survival after cytotoxic insult. Our results indicate that, with the exception of a small protective effect on one cell line (MDA-MB-435) treated with radiation, rHuEPO treatment alone or combined with cytotoxic therapy does not cause increased cell survival. Previous studies have shown mixed results with regards to tumor cell proliferation, chemoprotection, and/or treatment resistance in response to EPO (39-42). In line with this results of our study, work by Liu et al. showed no chemoprotective effect of EPO(40), whereas studies by Belenkov et al. showed a survival benefit with EPO in combination with radiotherapy (41) and Liang et al. showed unfavorable drug interactions between EPO and trastuzumab (42).
Although mimicking specific steps in metastasis \textit{in vitro} allows for controlled experiments, there are two main drawbacks to these types of assays. First, assays are often carried out using individual immortalized cancer cell lines which may or may not have the same characteristics of heterogeneous clinical disease. Secondly, and more importantly, \textit{in vitro} studies are limited to studying the effect of a factor on tumor cells alone, rather than being able to also take into account the influence of the tumor microenvironment. Interactions between cancer cells and their immediate microenvironment as well as the organ microenvironment in distant metastatic sites have been shown to be critically important for influencing metastatic behavior (43). Thus, the complexity of the metastatic process is such that the only way to comprehensively study metastasis is to use \textit{in vivo} model systems.

For these reasons, we conducted \textit{in vivo} assays using two different human breast cancer cell lines (MDA-MB-231 and MDA-MB-435) of differing genetic backgrounds, metastatic abilities, and EPOR protein expression together with a clinically relevant mouse model in which breast cancer cells can be injected orthotopically into the mammary fat pad and allowed to spontaneously metastasize to distant organs (44). In striking contrast to our \textit{in vitro} findings, our \textit{in vivo} results indicate that rHuEPO can reduce the efficacy of chemotherapy in the metastatic setting, and in some cases enhance the inherent metastatic growth potential of human breast cancer cells. Previously, rHuEPO has been shown to increase primary tumor growth of Lewis lung carcinoma cells (cells lacking demonstrable cell surface EPOR) (45), however in other studies investigating different types of tumors, no growth-enhancing effect of rHuEPO was seen (46-49). Increased chemotherapeutic response of the primary tumor has been shown (46,
48) and in one case an in vivo increase in radiosensitivity in response to rHuEPO was observed (47). Additional recent work by Liang et al. (2010) has shown an EPO-mediated reversal of the effects of the anti-HER2 therapy Trastuzumab on primary tumor growth, indicating that the signaling pathways inhibited by Trastuzumab (PI3K/Akt and Erk) may be in turn disrupted by rHuEPO (42). However, none of these studies evaluated metastasis, and in many cases doses of rHuEPO were considerably higher (from 1000U/kg biweekly (46) to 1000U/kg three times a week (47)) than the normal clinical dose range of 300-600U/kg used in cancer patients (31).

Interestingly, in the current study we observed that the growth-promoting influence of rHuEPO and chemoprotective effects at the metastatic site were more pronounced in mice injected with the moderately metastatic MDA-MB-231 cell line which expressed EPOR protein. However, mice injected with the highly metastatic MDA-MB-435 (which did not express detectable levels of EPOR protein) also showed additional enhancement of metastatic growth in the presence of rHuEPO alone, suggesting that the influence of rHuEPO may either act directly on tumor cells through both EPOR-dependent and EPOR–independent pathways. However, taken together with the observed minimal in vitro effect of rHuEPO on breast cancer cell behavior, we believe another more likely explanation is that in our model rHuEPO is acting via EPOR-related signaling directly on host microenvironmental cells, effecting their functionality and in turn promoting tumor cell survival. This could involve rHuEPO binding to its receptor on microenvironmental cells and initiating signaling that results in numerous host effects, including vasculogenesis, increased MMP production, endothelial progenitor mobilization, and increased thrombosis (50, 51). Importantly, these parameters are not
usually monitored clinically after rHuEPO is given (31), although studies have shown that activation of these processes can also enhance metastasis (52). In the case of thrombosis, an increase in the formation of microthrombi may increase the metastatic burden (53) and could account for the results seen in this study, although this was not investigated due to technical challenges associated with accurately assessing coagulation parameters in mice (53). Interestingly, multiple rHuEPO trials have reported increases in thrombotic events in the EPO arm (6, 8, 11, 54), and taken together with our pre-clinical data showing effects on metastasis without any observed direct effects on cancer cells, it is possible that this may be a factor leading to disease progression and decreased patient survival.

In summary, there have been a large number trials investigating ESAs for the treatment of CIA in cancer patients (5, 10-15, 32). In several trials, an increase in thrombotic events was seen in the ESA arm (6, 8, 11, 54). More importantly, meta-analyses demonstrate a decrease in overall survival in the ESA arm of some studies (6, 8). This has prompted concern about the use of rHuEPO in cancer patients with anemia because, while the cause of this decreased survival is unknown, it has been speculated that the administration of rHuEPO may cause cancer progression (8, 10). The current pre-clinical study aimed to shed some light on the observed clinical effect of rHuEPO by investigating the expression and function of EPOR in pre-clinical model systems of human breast cancer metastasis. Our novel findings indicate that rHuEPO can reduce the efficacy of chemotherapy in the metastatic setting and in some cases enhance the inherent metastatic growth potential of human breast cancer cells, potentially due to indirect effects of rHuEPO on the host rather than just direct effects on tumor cells. These studies
highlight the importance of using clinically-relevant *in vivo* models to investigate disease progression, and may help to explain the underlying functional cause of the observed EPO-related adverse events and decreased survival in ESA-treated metastatic breast cancer patients undergoing chemotherapy.

**ACKNOWLEDGEMENTS**

We thank Carl Postenka for help with the histopathological studies and Richard Plante for his insight throughout the study.
REFERENCES


## Supplemental Table 1 - Cell lines used

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Source</th>
<th>Culturing conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCI-H838</td>
<td>American Type Culture Collection (ATCC; Manassas, VA, USA)</td>
<td>RPMI 1640 + 10% FBS supplemented to a final concentration of 25mM D-glucose and 1mM sodium pyruvate</td>
</tr>
<tr>
<td>MDA-MB-231</td>
<td>Dr. Janet Price (M.D. Anderson Cancer Center, Houston, TX, USA)</td>
<td>DMEM:F12 + 5% FBS</td>
</tr>
<tr>
<td>MDA-MB-435</td>
<td></td>
<td>DMEM:F12 + 5% FBS</td>
</tr>
<tr>
<td>MDA-MB-468</td>
<td></td>
<td>αMEM + 10% FBS</td>
</tr>
<tr>
<td>4T1</td>
<td>Dr. Fred Miller (Wayne State University, Detroit, MI)</td>
<td>RPMI 1640 + 10% FBS supplemented to final concentrations of 1mM sodium pyruvate and 10mM HEPES</td>
</tr>
<tr>
<td>UT7/EPO</td>
<td>Dr. Francis Farrell (Discovery Research, Centocor R&amp;D, PA, USA)</td>
<td>αMEM + 20% FBS + 1U/mL epoetin alfa (Eprex, Janssen-Ortho Inc., ON, Canada)</td>
</tr>
<tr>
<td>NIH 3T3</td>
<td>Dr. Ann Chambers (London Regional Cancer Program, London ON, Canada)</td>
<td>DMEM + 10% FBS</td>
</tr>
</tbody>
</table>
## Supplemental Table 2 - PCR primers and cycling conditions

<table>
<thead>
<tr>
<th>Gene</th>
<th>Direction</th>
<th>Sequence</th>
<th>Expected Product (bp)</th>
<th>Cycling conditions*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Denaturation</td>
</tr>
<tr>
<td>Human</td>
<td>Forward</td>
<td>5'-GGAGATCCTGGAGGGCCGCA-3'</td>
<td>290</td>
<td>30 sec</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>5'-ACTCGCTCTCTGGGCTCGGG-3'</td>
<td></td>
<td>94°C</td>
</tr>
<tr>
<td>Mouse</td>
<td>Forward</td>
<td>5'-CAAAGGCCCAGGCCAGAGGC-3'</td>
<td>288</td>
<td>30 sec</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>5'-GCAGGCCACATAGCCGGG-3'</td>
<td></td>
<td>95 °C</td>
</tr>
<tr>
<td>Human</td>
<td>Forward</td>
<td>5'-TCAGGCTCTTCGAGAAGCATCA-3'</td>
<td>395</td>
<td>30 sec</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>5'-TTAGATTACGCCGACCAGCACTG-3'</td>
<td></td>
<td>94 °C</td>
</tr>
<tr>
<td>Mouse JAK2</td>
<td>Forward</td>
<td>5'-ACGAGTCAACCAGGCATGAC-3'</td>
<td>342</td>
<td>30 sec</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>5'-GGATCTCGCTCGACGAC-3'</td>
<td></td>
<td>94 °C</td>
</tr>
<tr>
<td>Human and Mouse</td>
<td>Forward</td>
<td>5'-CATGGTTTGATGTCATGGTGTAACCA-3'</td>
<td>152</td>
<td>20 sec</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Reverse</td>
<td>ATGGCATGGACTGTGTCATGAGT-3'</td>
<td></td>
<td>95 °C</td>
</tr>
</tbody>
</table>

*Reaction composition: 1X Buffer, 0.2mM dNTP, 2.5mM MgCl₂, 1U Taq, 0.5µM Forward and Reverse Primer, 1µL cDNA as prepared from the reverse transcriptase reaction. All reagents were from Invitrogen.
### Supplemental Table 3 - Anti-human EPOR antibodies

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Applications</th>
<th>Western Blot</th>
<th>Flow Cytometry</th>
<th>Comments</th>
<th>Assessed</th>
<th>Blocked</th>
<th>ERPO Staining</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>R&amp;D Systems</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>Yes</td>
<td></td>
<td>UT7/EPO and H838 positive</td>
</tr>
<tr>
<td>MAB307</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imgenex IMG-3771</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>N/A</td>
<td>Multiple bands detected. Results not reproducible.</td>
<td>N/A</td>
</tr>
<tr>
<td>Santa Cruz Sc-697</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>No</td>
<td>Multiple bands detected. None blocked by rHuEPOR. Results not reproducible.</td>
<td>-</td>
</tr>
<tr>
<td>Santa Cruz Sc-80030</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>No</td>
<td>Multiple bands detected. None blocked by rHuEPOR. Results not reproducible.</td>
<td>-</td>
</tr>
</tbody>
</table>

✓ = Assessed  
✗ = Not assessed  
N/A = Not available
Supplemental Table 4 - *In vivo* hemoglobin measurements\(^a\).

<table>
<thead>
<tr>
<th>Mouse strain</th>
<th>Baseline Hb (g/L)</th>
<th>EPO dose (U/kg)</th>
<th>Increase in Hb levels after 9 weeks (g/L) ± SEM</th>
<th>Correlation coefficient with LH 780</th>
<th>Intercept</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOD/SCID</td>
<td>136.5 ± 2.0</td>
<td>0</td>
<td>1.6 ± 2.3</td>
<td>0.8579</td>
<td>+17</td>
</tr>
<tr>
<td></td>
<td></td>
<td>300</td>
<td>19.6 ± 4.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>600</td>
<td>20.9 ± 6.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1200</td>
<td>33.7 ± 4.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>nu/nu</em></td>
<td>129.4 ± 2.0</td>
<td>0</td>
<td>5.1 ± 6.3</td>
<td>0.8477</td>
<td>+14</td>
</tr>
<tr>
<td></td>
<td></td>
<td>300</td>
<td>30.0 ± 6.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>600</td>
<td>31.9 ± 6.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1200</td>
<td>43.7 ± 5.2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^a\)An *in vivo* dose-finding experiment was carried out to determine a dose of rHuEPO to minimize any adverse polycythemia and thromboembolic events. Female NOD/SCID or *nu/nu* mice were respectively injected with MDA-MB-231 or MDA-MB-435 human breast cancer cells via the mammary fat pad. Three weeks post-injection, control cohorts received weekly saline subcutaneous injections (n=4), while other groups received rHuEPO (300 U/kg, 600 U/kg, or 1200 U/kg [n=4 per group]). Blood was collected via weekly saphenous vein puncture and hemoglobin (Hb) levels were determined by colorimetric assay (BioPacific Diagnostics) at each time point. To determine the accuracy of the colorimetric assay at endpoint (9 weeks), blood was collected via saphenous vein and cardiac puncture and Hb levels were determined by colorimetric assay and compared to results from a calibrated LH 780 hematology analyzer (Beckman Coulter).
FIGURE LEGENDS

Figure 1. EPO-related molecular characteristics in cell lines. UT7/EPO (human acute myeloid leukemia cells), NIH 3T3 (3T3; mouse fibroblast cells), NCI-H838 (H838; human non-small cell lung cancer cells), MDA-MB-231, MDA-MB-435, MDA-MB-468 (231, 435, 468; human breast cancer cells), and 4T1 (mouse mammary cancer cells) were incubated in the absence or presence (*) of 10U/mL rHuEPO for 5 minutes prior to sample collection. (A) Reverse Transcriptase PCR analysis of EPOR and JAK2 mRNA expression in mouse bone marrow (mBM) and cell lines. (B) Western blot analysis of EPOR protein levels in 30μg of total protein using the anti-EPOR antibody, MAB307 (R&D Systems). Expected size of EPOR is between 52-60 kDa (19). (C) The specificity of the MAB307 antibody was determined by carrying out an overnight blocking step using a two-fold excess concentration of rhEPOR (R&D Systems). (D) Flow cytometry analysis of UT7/EPO, NCI-H838, MDA-MB-435, MDA-MB-231, MDA-MB-468 and 4T1 cell lines for EPOR cell surface protein expression using the MAB307 primary antibody and a PE-conjugated secondary antibody (black profiles). An IgG isotype control (white profiles) indicates the baseline fluorescence levels for each cell line. (E) ELISA-based assessment of cell-secreted endogenous EPO levels for the UT7/EPO, MDA-MB-435, MDA-MB-231, MDA-MB-468 and 4T1 cell lines. The dashed line indicates the minimum sensitivity of the assay; all results below the line are considered negative.
Figure 2. Effect of rHuEPO on *in vitro* growth characteristics of MDA-MB-231 (231) and MDA-MB-435 (435) human breast cancer cells. Cells were cultured in the absence (*white bars*) or presence (*black bars*) of rHuEPO (10 U/mL) for the duration of the assays. *(A)* Doubling time of cells grown under normal anchorage-dependent (2-dimensional) culture conditions. 5.0 x 10⁴ cells/60mm dish (n=3 per time point) were cultured and counted by hemocytometer every 48 hours for 14 days. *(B)* Plating efficiency of cells in anchorage-dependent (2-dimensional) culture. 100 cells/60mm dish (n=3) were plated and allowed to grow for 2 weeks. Colonies were stained and counted as described in the Materials and Methods. Data is expressed as a % of expected (100) colonies formed. *(C, D)* Anchorage-independent (3-dimensional) growth. Cells (4x10⁴ cells/60 mm plate, n=4 plates per treatment) were grown in soft agar (0.3%) for 3-4 weeks. Plates were scanned at 100X magnification and 5 fields of view (FOV) were counted for each dish. *(C)* Average number of colonies per FOV. *(D)* Average diameter of colonies (μm). All data are presented as the mean ± SEM. No statistical differences were observed in any of the assays (p> 0.05).

Figure 3. Effect of rHuEPO in combination with radiation, chemotherapy or hypoxia treatment on *in vitro* cell survival of MDA-MB-231 (231) and MDA-MB-435 (435) human breast cancer cells. Following treatment, media was collected from all samples and cells were detached from the plate by 0.125% Trypsin-1mM EDTA and added to the media. After centrifugation, all cells were stained with PI (50 μg/mL) and analyzed by flow cytometry to assess the degree of cell survival, with PI exclusion being an indicator of viable cells. For all assays, the proportion of cells recovered at time of...
analysis from each group was approximately the same. All data are normalized to their respective “cells only” control and are presented as the mean ± SEM. (A, B) Cell survival in the presence of radiation (A) or chemotherapy (B) treatment. Cells (1 x 10^5 cells) were plated in triplicate in 6 well plates ± rHuEPO (10U/mL) and allowed to grow to 60-70% confluency. Cells were (A) subjected to 2 fractions of 5 Gray of radiation separated by 24 hours or (B) treated with 10mg/mL Paclitaxel. After treatment, cells were incubated for a further 24 hours. (A) # indicates a statistically significant difference from the cells only (untreated) control (MDA-MB-231 p=0.0075; MDA-MB-435 p<0.0001); * represents a statistically significant difference from the radiation treated cells. (B) # indicates a statistically significant difference from the cells only (untreated) control (MDA-MB-231 p=0.0099; MDA-MB-435 p<0.0001). (C) Cell survival under hypoxic conditions. 5 x 10^5 MDA-MB-231 or MDA-MB-435 cells were plated per 60mm dish (n=3) 24 or 48 hours, respectively, prior to treatment. Cells were grown in normoxic conditions or subjected to hypoxic conditions (1% O₂, 5% CO₂, 94% N₂) for 24 hours (MDA-MB-231) or 48 hours (MDA-MB-435) in the presence or absence of 10U/mL EPO. # indicates a statistically significant difference from the cells only (untreated) control (p<0.0001).

**Figure 4. Effect of rHuEPO on in vivo tumorigenicity of MDA-MB-231 and MDA-MB-435 human breast cancer cells.** Cells (2 x 10^6) were injected into the right thoracic mammary fat pad of 6-7 week old female NOD/SCID (MDA-MB-231 cells) or nude (nu/nu) (MDA-MB-435 cells) mice (n=12 per group) and allowed to grow for 10 weeks. Weekly tumor measurements were taken using digital calipers. Primary tumor growth over time of (A) MDA-MB-231 or (B) MDA-MB-435 tumors. rHuEPO treatment (300
U/kg) was started at 3 weeks post injection (black arrow), while Paclitaxel treatment (10 mg/kg) was initiated at 5 weeks post tumor cell injection (white arrow). Data are presented as the mean ± SEM. (A) # indicates significant difference from the control group p<0.001. (B) No statistically significant differences were observed.

**Figure 5. Effect of rHuEPO on in vivo metastatic capability of MDA-MB-231 and MDA-MB-435 human breast cancer cells.** Cells (2 x 10^6) were injected into the right thoracic mammary fat pad of 6-7 week old female NOD/SCID (MDA-MB-231 cells) or nude (nu/nu) (MDA-MB-435 cells) mice (n=12 per group) and allowed to grow for 12 weeks. Mice were then sacrificed and assessed by histopathology for metastasis to distant organs. (A-C) NOD/SCID mice injected with MDA-MB-231 cells. (D-F) nude mice injected with MDA-MB-435 cells. (A,D) Incidence of lung metastasis (% of mice in each treatment group that developed metastases). (B,E) Size (diameter) of lung metastases scored. Data are presented as the mean ± SEM. (C,F) Lung metastatic tumor burden (% of total lung volume occupied by tumor). Data are presented as the mean ± SEM. For all panels, # denotes a statistically significant difference relative to the untreated control cohort (p<0.01); and * indicates a statistically significant difference relative to the Paclitaxel only treatment cohort (p<0.001).

**Supplemental Figure 1. Densitometric analysis of PCR bands (Figure 1A).** EPOR and JAK2 amplification was normalized to GAPDH intensity for mBM, UT7/EPO, 3T3, H838, MDA-MB-435, MDA-MB-231, MDA-MB-468 and 4T1 samples, with (*) or without rHuEPO treatment and subjected to densitometric analysis.
Supplemental Figure 2. Results of rHuEPO in vivo dose finding experiment. 2 x 10^6 MDA-MB-231 or MDA-MB-435 cells were injected into 6- to 7-week-old female NOD/SCID or nu/nu mice via mammary fat pad. The control cohort (n=4) received weekly saline subcutaneous injections, while three other cohorts (n=4 per group) received rHuEPO doses of 300U/kg, 600U/kg or 1200U/kg. (A-D) Data from MDA-MB-231 breast cancer cells in NOD/SCID mice. (E-H) Results from MDA-MB-435 breast cancer cells injected into nude (nu/nu) mice. (A,E) Primary tumor growth of human breast cancer cells injected into mice over time. EPO treatment was initiated at 3 weeks post injection (black arrow). Data are presented as mean ± SEM. (B,F) Incidence of lung metastasis (% of mice in each treatment group that developed metastases). (C,G) Size (diameter) of lung metastases scored. Data are presented as mean ± SEM. (D,H) Number of lung metastases observed. Data are presented as the mean ± SEM. For all panels, # denotes a statistically significant difference relative to the untreated control cohort (p<0.05).
Figure 1. Hedley and Chu et al., 2010

(A) 

(B) 

(C) 

(D) 

(E)
Figure 2. Hedley and Chu et al., 2010

A

B

C

D

Author Manuscript Published OnlineFirst on August 19, 2011; DOI: 10.1158/1078-0432.CCR-10-3298
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Figure 4. Hadley and Chu et al., 2010

A

B

Mean Tumor Volume (mm³)

Days Post Injection

Mean Tumor Volume (mm³)

Days Post Injection
Recombinant human erythropoietin (rHuEPO) in combination with chemotherapy increases breast cancer metastasis in pre-clinical mouse models

Benjamin D. Hedley, Jenny E. Chu, David G. Ormond, et al.

Clin Cancer Res Published OnlineFirst August 19, 2011.

Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-10-3298

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2011/08/19/1078-0432.CCR-10-3298.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.